CoChat

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma

Open access

The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.

Abstract

High metabolic tumor volume (MTV) predicts worse outcomes in lymphoma treated with chemotherapy. However, it is unknown if this holds for patients treated with axicabtagene ciloleucel (axi-cel), an anti-CD19 targeted chimeric antigen receptor T-cell therapy. The primary objective of this retrospective study was to investigate the relationship between MTV and survival (overall survival [OS] and progression-free survival [PFS]) in patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axi-cel. Secondary objectives included finding the association of MTV with response rates and toxicity. The MTV values on baseline positron emission tomography of 96 patients were calculated via manual methodology using commercial software. Based on a median MTV cutoff value of 147.5 mL in the first cohort (n = 48), patients were divided into high and low MTV groups. Median follow-up for survivors was 24.98 months (range, 10.59-51.02 months). Patients with low MTV had significantly superior OS (hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.10-0.66) and PFS (HR, 0.40; 95% CI, 0.18-0.89). Results were successfully validated in a second cohort of 48 patients with a median follow-up for survivors of 12.03 months (range, 0.89-25.74 months). Patients with low MTV were found to have superior OS (HR, 0.14; 95% CI, 0.05-0.42) and PFS (HR, 0.29; 95% CI, 0.12-0.69). In conclusion, baseline MTV is associated with OS and PFS in axi-cel recipients with LBCL.

Overview

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2020001900

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

See all 256

Metadata

Authors
Dean, E. A., Mhaskar, R. S., Lu, H., Mousa, M. S., Krivenko, G. S., Lazaryan, A., Bachmeier, C. A., Chavez, J. C., Nishihori, T., Davila, M. L., Khimani, F., Liu, H. D., Pinilla-Ibarz, J., Shah, B. D., Jain, M. D., Balagurunathan, Y., & Locke, F. L.
Affiliations
  • Moffitt Cancer Center (US)
  • University of South Florida (US)
  • Tianjin Medical University Cancer Institute and Hospital (CN)
  • Department of Diagnostic Imaging and Interventional Radiology,
  • Department of Blood and Marrow Transplant and Cellular Immunotherapy, and
  • Department of Malignant Hematology, H. Lee Moffitt Cancer and Research Institute, Tampa, FL;
  • Department of Biostatistics and Bioinformatics, and
Venue
Blood Advances
Published
2020-07-23
Volume
4
Issue
14
Pages
3268-3276
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3044532926
Cited by
256
References
22
Citations by year
2026: 29 · 2025: 42 · 2024: 48 · 2023: 52 · 2022: 44 · 2021: 36 · 2020: 4
FWCI
12.28
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Commons - University of South Florida (University of South Florida) (submittedVersion)
Funders
National Cancer Institute (K23CA201594, P30CA076292)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Keywords
metabolic tumor volume, axicabtagene ciloleucel, large B-cell lymphoma, relapsed/refractory lymphoma, CAR T-cell therapy, anti-CD19, overall survival, progression-free survival, prognostic factors, positron emission tomography, treatment response, toxicity
MeSH terms
Biological Products, Humans, Retrospective Studies, Immunotherapy, Adoptive, Antigens, CD19, Tumor Burden

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. https://app.cochat.ai/papers/10.1182/bloodadvances.2020001900
The paper
Dean, E. A., Mhaskar, R. S., Lu, H., Mousa, M. S., Krivenko, G. S., Lazaryan, A., Bachmeier, C. A., Chavez, J. C., Nishihori, T., Davila, M. L., Khimani, F., Liu, H. D., Pinilla-Ibarz, J., Shah, B. D., Jain, M. D., Balagurunathan, Y., & Locke, F. L. (2020). High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. https://doi.org/10.1182/bloodadvances.2020001900

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.